Chinese regulators are closely examining the pricing methods of local and foreign drugmakers for any antitrust violations, according to a state-run financial newspaper, as the government conducts a wide-ranging campaign to regulate prices of medicines.
Antitrust watchdogs are looking for violations such as price manipulation among competitors or via the distribution chain, according to a report by the Securities Times, which cited a recent speech in Shanghai by Lu Yanchun, deputy head of the National Development and Reform Commission’s price supervision and anti-monopoly bureau.
Some foreign pharmaceutical companies try to prevent generic drugs from entering the market by applying for new patents on old drugs whose original patents are close to expiration, without substantially changing the efficacy of the medicines, Lu said, according to the Securities Times.
R&D-based Pharmaceutical Association Committee, an industry group representing foreign drugmakers did not respond to a request for comment.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI